脓毒症与脓毒性休克的经验性治疗及头孢地尔在治疗中的地位:系统综述与专家意见
碳青霉烯耐药革兰阴性菌是ICU脓毒症与脓毒性休克的常见病因,尤其产金属β-内酰胺酶(MBL)菌株使现有β-内酰胺酶抑制剂联合方案失效,存在未满足的医疗需求。头孢地尔经静脉给药,已被FDA和EMA批准用于治疗复杂尿路感染和医院获得性肺炎(革兰阴性菌、治疗选择有限时),其劫持细菌铁摄取机制使其对全部Ambler β-内酰胺酶稳定,并增强对肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌的体外活性。试验已证明其非劣效于对照药物;2021年ESCMID指南条件性推荐头孢地尔用于产MBL肠杆菌目和鲍曼不动杆菌。本综述通过系统检索提供ICU脓毒症与脓毒性休克经验性治疗的专家意见,并确定头孢地尔在治疗中的合理定位。
要点
- 碳青霉烯耐药革兰阴性菌是ICU脓毒症与脓毒性休克的常见病因,产MBL菌株使现有β-内酰胺酶抑制剂联合方案失效。
- 头孢地尔静脉给药获FDA和EMA批准用于复杂尿路感染和医院获得性肺炎(革兰阴性菌、治疗选择有限时)。
- 头孢地尔对全部Ambler β-内酰胺酶稳定,体外对肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌活性增强。
- 试验已证明头孢地尔非劣效于对照药物。
- 2021年ESCMID指南条件性推荐头孢地尔用于产MBL肠杆菌目和鲍曼不动杆菌。
适用人群与场景
- ICU中脓毒症与脓毒性休克患者,经验性治疗需覆盖碳青霉烯耐药革兰阴性菌。
处置流程与药物剂量
- 头孢地尔静脉给药,获批用于复杂尿路感染和医院获得性肺炎(革兰阴性菌、治疗选择有限时)。
研究设计与关键结果
- 系统综述与专家意见:通过系统检索提供ICU脓毒症与脓毒性休克经验性治疗及头孢地尔定位的专家意见。
- 头孢地尔对全部Ambler β-内酰胺酶稳定,体外对肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌活性增强。
- 试验已证明头孢地尔非劣效于对照药物。
证据类型、等级与局限
- 证据类型:系统综述与专家意见。
- 2021年ESCMID指南条件性推荐头孢地尔用于产MBL肠杆菌目和鲍曼不动杆菌。
- 局限:原文未报告局限性
对床旁实践的改变
- 2021年ESCMID指南条件性推荐头孢地尔用于产MBL肠杆菌目和鲍曼不动杆菌。
指南或共识出处
- 2021年ESCMID指南
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Carbapenem-resistant Gram-negative bacteria are frequent causes of sepsis and septic shock in intensive care unit (ICU) and thus considered a public health threat. Until now, the best available therapies consist of combinations of preexisting or new antibiotics with β-lactamase inhibitors (either new or preexisting). Several mechanisms of resistance, especially those mediated by metallo-β-lactamases (MBL), are responsible for the inefficacy of these treatments, leaving an unmet medical need. Intravenous cefiderocol has been recently approved by the American Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of complicated urinary tract infections and nosocomial pneumonia due to Gram-negative, when limited therapeutical options are available. In addition, its ability to hijack bacterial iron uptake mechanisms makes cefiderocol stable against the whole Ambler β-lactamase inhibitors and increases the in vitro efficacy against Gram-negative pathogens (e.g., Enterobacterales spp., Pseudomonas aeruginosa, and Acinetobacter baumannii). Trials have already demonstrated their non-inferiority to comparators. In 2021, ESCMID guidelines released a conditional recommendation supporting the use of cefiderocol against metallo-β-lactamase-producing Enterobacterales and against Acinetobacter baumannii. This review provides the opinion of experts about the general management of empiric treatment of patients with sepsis and septic shock in the intensive care unit and detects the proper place in therapy of cefiderocol considering recent evidence sought through a systematic search.
参考来源
- Cortegiani A, Ingoglia G, Ippolito M, et al. Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement. J Anesth Analg Crit Care. 2022. PMID: 37386663. doi:10.1186/s44158-022-00062-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。